The evidence presented on the role of osteoblasts and osteoclasts activity during EPO‐stimulated erythropoietic response seems likely to further fuel the debate on the relative efficacy and safety of EPO vs HIF‐PHIs for patients who require long‐term treatment for anemia. The gene discussed is EPO; the disease is anemia.